Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 28, Issue 4, p.549-55 (2010)


2010, Adenine Nucleotides, Aged, Aged, 80 and over, Antineoplastic Agents, Arabinonucleosides, Center-Authored Paper, Clinical Research Division, Female, Follow-Up Studies, Humans, Leukemia, Myeloid, Acute, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Prospective Studies, Remission Induction, Survival Rate, Treatment Outcome


This phase II study assessed clofarabine monotherapy in older adults (>or= 60 years of age) with untreated acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor.